keyword
MENU ▼
Read by QxMD icon Read
search

Eylea

keyword
https://www.readbyqxmd.com/read/27721789/treatment-of-retinitis-pigmentosa-associated-cystoid-macular-oedema-using-intravitreal-aflibercept-eylea-despite-minimal-response-to-ranibizumab-lucentis-a-case-report
#1
Stacey A Strong, Avinash Gurbaxani, Michel Michaelides
BACKGROUND: We present an interesting case of bilateral retinitis pigmentosa (RP)-associated cystoid macular oedema that responded on two separate occasions to intravitreal injections of aflibercept, despite previously demonstrating only minimal response to intravitreal ranibizumab. This unique case would support a trial of intravitreal aflibercept for the treatment of RP-associated cystoid macular oedema. CASE PRESENTATION: A 38-year-old man from Dubai, United Arab Emirates, presented to the UK with a 3-year history of bilateral RP-associated cystoid macular oedema...
May 2016: Case Reports in Ophthalmology
https://www.readbyqxmd.com/read/27631479/aflibercept-for-diabetic-macular-edema-in-eyes-previously-treated-with-ranibizumab-and-or-bevacizumab-may-further-improve-macular-thickness
#2
Chirag P Shah, Jeffrey S Heier
BACKGROUND AND OBJECTIVE: To evaluate the short-term anatomic and visual outcomes after aflibercept (Eylea; Regeneron, Tarrytown, NY) in eyes with diabetic macular edema (DME) previously treated with ranibizumab (Lucentis; Genentech, South San Francisco, CA) and/or bevacizumab (Avastin; Genentech, South San Francisco, CA). PATIENTS AND METHODS: A single-center, retrospective, noncomparative study of 30 eyes in 23 patients with DME treated with prior ranibizumab and/or bevacizumab before switching to aflibercept...
September 1, 2016: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/27615995/study-of-stability-and-biophysical-characterization-of-ranibizumab-and-aflibercept
#3
M R Moreno, T S Tabitha, J Nirmal, K Radhakrishnan, C H Yee, S Lim, S Venkatraman, R Agrawal
The anti-vascular endothelial growth factor (VEGF) agents such as ranibizumab (Lucentis®) and aflibercept (EyLea®) are currently used as monthly or bimonthly intravitreal injections to treat potentially blinding retinal diseases such as wet age-related macular degeneration (AMD) or diabetic macular edema (DME). Because of the complications associated with repeated intra-vitreal injections, there is considerable interest in developing a sustained delivery system. The purpose of this study was to examine the stability of both therapeutic proteins under physiological conditions as well as when incorporated into drug delivery systems (DDS)...
September 8, 2016: European Journal of Pharmaceutics and Biopharmaceutics
https://www.readbyqxmd.com/read/27440854/air-entry-into-the-anterior-chamber-post-intravitreal-injection-of-eylea
#4
Wei Sing Lim, Munir Sikandar, Heather Jackson
An 84-year-old man had air entry into the anterior chamber following intravitreal injection. The air bubble was reabsorbed over time without any complications. No further problems occurred with subsequent intravitreal injections.
2016: BMJ Case Reports
https://www.readbyqxmd.com/read/27348433/the-role-of-anti-vegf-therapy-in-the-treatment-of-diabetic-macular-edema
#5
Darius M Moshfeghi, Peter K Kaiser, Stephan Michels, Edoardo Midena, John W Kitchens, Jonathan L Prenner, Carl D Regillo, Elias Reichel
Diabetic retinopathy (DR) is the leading cause of blindness among working-age adults. DR often leads to diabetic macular edema (DME), which often goes unnoticed until a patient presents with vision loss. However, treatment options and data for DME are continually improving. We know that vascular endothelial growth factor (VEGF) plays a key role in DME progression; therapies that act by inhibiting VEGF production seem to improve visual acuity in patients with DME. Of the anti-VEGF therapies available, two have been approved by the U...
June 2016: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/27348231/aflibercept-as-first-line-therapy-in-patients-with-treatment-na%C3%A3-ve-neovascular-age-related-macular-degeneration-prospective-case-series-analysis-in-real-life-clinical-practice
#6
Patricia Udaondo, David Salom, Salvador García-Delpech, Ángel Cisneros-Lanuza
PURPOSE: To assess the 13-month effectiveness and safety of aflibercept in naïve patients with neovascular age-related macular degeneration (nvAMD) in a real-life clinical setting. METHODS: Thirty-two treatment-naïve patients with nvAMD participated in a prospective two-center study. Patients received intravitreal injections of aflibercept (Eylea®), a loading dose of three monthly injections (2 mg/0.05 ml) every 4 weeks for the first 3 months, followed by intravitreal injections every 2 months...
2016: Ophthalmologica. Journal International D'ophtalmologie
https://www.readbyqxmd.com/read/27327292/macular-telangiectasia-type-1-managed-with-long-term-aflibercept-therapy
#7
Jaclyn L Kovach, Harald Hess, Philip J Rosenfeld
A 60-year-old man diagnosed with macular telangiectasia type 1 (MacTel 1) was treated for 3 years with monthly aflibercept (Eylea; Regeneron, Tarrytown, NY) and serially imaged with spectral-domain optical coherence tomography. When administered monthly, aflibercept appeared to have a beneficial effect on macular edema secondary to MacTel 1. Visual acuity preservation despite minimal chronic macular edema could be attributed to the lack of significant photoreceptor disruption. [Ophthalmic Surg Lasers Imaging Retina...
June 1, 2016: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/27327285/physician-utilization-patterns-for-vegf-inhibitor-drugs-in-the-2012-united-states-medicare-population-bevacizumab-ranibizumab-and-aflibercept
#8
Shivani Baisiwala, M Kate Bundorf, Suzann Pershing
BACKGROUND AND OBJECTIVE: To evaluate variation in physician use of vascular endothelial growth factor (VEGF) inhibitors. PATIENTS AND METHODS: Population-based analysis of comprehensive, publicly available 2012 Medicare claims, aggregated by physician specialty and service type - including intravitreal injections of bevacizumab (Avastin; Genentech, South San Francisco, CA), ranibizumab (Lucentis; Genetech, South San Francisco, CA), and aflibercept (Eylea; Regeneron, Tarrytown, NY)...
June 1, 2016: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/27327284/retina-specialists-treating-diabetic-macular-edema-recommend-different-approaches-for-patients-than-they-would-choose-for-themselves
#9
Charles G Miller, Greg Budoff, Karen W Jeng-Miller, Howard F Fine, Daniel B Roth, Jonathan L Prenner
BACKGROUND AND OBJECTIVE: Prior investigation shows retina specialists may select different treatment for age-related macular degeneration for themselves than for a hypothetical patient. The authors sought to investigate whether a similar bias exists for treatment decisions by retina specialists with regard to diabetic macular edema (DME). PATIENTS AND METHODS: Two surveys asked retina specialists to select treatment for hypothetical patients with DME or for themselves...
June 1, 2016: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/27258433/intraocular-pharmacokinetics-of-intravitreal-aflibercept-eylea-in-a-rabbit-model
#10
Sang Jun Park, Yewon Choi, Young Mi Na, Hye Kyoung Hong, Ji Yeon Park, Kyu Hyung Park, Jae Yong Chung, Se Joon Woo
Purpose: We determined the intraocular pharmacokinetic properties of intravitreally injected aflibercept (Eylea) in a rabbit model. Methods: Aflibercept was injected intravitreally in 21 eyes from New Zealand White rabbits. The eyes were enucleated 1, 24, 48, 120, 216, 360, and 720 hours (1, 2, 5, 9, 15, and 30 days, respectively) after injection and immediately frozen at -80°C. The concentrations of aflibercept in the vitreous, aqueous humor, and retina/choroid were determined by performing an indirect enzyme-linked immunosorbent assay, and analyzed to understand the pharmacokinetic properties of the drug...
May 1, 2016: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/27236451/safety-and-complications-of-intravitreal-injections-performed-in-an-asian-population-in-singapore
#11
Yanping Xu, Colin S Tan
There has been a rapid rise in the use of intravitreal injections, such as anti-vascular endothelial growth factor (anti-VEGF) agents, performed over the past few years for the treatment of ocular neovascular diseases. This study aims to review the systemic and ocular adverse events among patients treated at a tertiary eye center over a period of 8 years. A retrospective review of all intravitreal injections of anti-VEGF performed over an 8-year period at a tertiary eye care center in Singapore was done. We report the frequency of systemic and ocular adverse events and compared it among the various anti-VEGF agents...
May 28, 2016: International Ophthalmology
https://www.readbyqxmd.com/read/27190127/three-month-outcome-of-intravitreal-ziv-aflibercept-in-eyes-with-diabetic-macular-oedema
#12
Ahmad M Mansour, Chintan Dedhia, Jay Chhablani
PURPOSE: We report the 3-month efficacy of monthly intravitreal ziv-aflibercept in patients with diabetic macular oedema (DME). METHODS: Prospectively, consecutive patients with DME underwent intravitreal injection of 0.05 ml of compounded ziv-aflibercept (1.25 mg) from March 2015 to November 2015. Monitoring of best-corrected visual acuity (BCVA), intraocular inflammation, cataract progression and retinal structure by spectral domain optical coherence tomography was carried out at baseline, 1 week, 1 month, 2 months and 3 months after 3 monthly injections...
May 17, 2016: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/27183554/progressive-release-of-vitreomacular-traction-with-aflibercept
#13
Stephen G Schwartz, Harry W Flynn
A patient with combined diabetic macular edema (DME) and vitreomacular traction (VMT) was treated with a series of intravitreal aflibercept (Eylea; Regeneron, Tarrytown, NY) injections. The VMT progressively released during the course of the five intravitreal injections. This release may have been spontaneous, due to a nonspecific mechanical effect from the injections, or due to a pharmacologic effect from the aflibercept. While treating DME, anti-vascular endothelial growth factor agents may have an additional benefit in releasing VMT...
May 1, 2016: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/27183553/reduction-of-diabetic-macular-edema-in-the-untreated-fellow-eye-following-intravitreal-injection-of-aflibercept
#14
Charles M Calvo, Jayanth Sridhar, Abtin Shahlaee, Allen C Ho
A 59-year-old patient with bilateral worsening diabetic macular edema received intravitreal injection of aflibercept (Eylea; Regeneron, Tarrytown, NY) to the left eye only. On 1-month follow-up, there was noted bilateral improvement of visual acuity and diabetic macular edema on spectral-domain optical coherence tomography imaging, reflecting bilateral effect of unilateral treatment with aflibercept. [Ophthalmic Surg Lasers Imaging Retina. 2016;47:474-476.].
May 1, 2016: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/27183550/factors-associated-with-poor-response-to-aflibercept-after-switching-from-ranibizumab-or-bevacizumab-in-neovascular-age-related-macular-degeneration
#15
Sarah Cheng, Theodore Leng
BACKGROUND AND OBJECTIVE: The purpose of this study was to analyze demographic and ocular features of patients with age-related macular degeneration who failed aflibercept (Eylea; Regeneron, Tarrytown, NY) treatment after switching from ranibizumab (Lucentis; Genentech, South San Francisco, CA) or bevacizumab (Avastin; Genentech, South San Francisco, CA). PATIENTS AND METHODS: Retrospective chart review of patients treated with aflibercept at the Byers Eye Institute from November 2011 to August 2014...
May 1, 2016: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/27115856/noninfectious-vitritis-after-intravitreal-injection-of-anti-vegf-agents-variations-in-rates-and-presentation-by-medication
#16
Patrick D Williams, Deborah Chong, Timothy Fuller, David Callanan
PURPOSE: The purpose of this study was to describe and compare the rates and characteristics of noninfectious vitritis after intravitreal injection of bevacizumab (Avastin, Genentech, South San Francisco, CA), ranibizumab (Lucentis, Genentech), and aflibercept (Eylea, Regeneron, Tarrytown, NY). METHODS: A retrospective case series evaluated intravitreal injections from 2006 to 2013. Cases of inflammatory response were separated into culture-positive endophthalmitis, noninfectious vitritis (not treated with intravitreal antibiotics), and indeterminate...
May 2016: Retina
https://www.readbyqxmd.com/read/27106625/the-effects-of-vegf-a-inhibitors-aflibercept-and-ranibizumab-on-the-ciliary-body-and-iris-of-monkeys
#17
Maximilian Ludinsky, Sarah Christner, Nan Su, Tatjana Taubitz, Alexander Tschulakow, Antje Biesemeier, Sylvie Julien-Schraermeyer, Ulrich Schraermeyer
PURPOSE: To investigate the effects of intravitreal ranibizumab (Lucentis®) and aflibercept (Eylea®) on the ciliary body and the iris of 12 cynomolgus monkeys with regard to the fenestrations of their blood vessels. MATERIALS AND METHODS: Structural changes in the ciliary body and in the iris were investigated with light, fluorescent, and transmission electron microscopy (TEM). The latter was used to specifically quantify fenestrations of the endothelium of blood vessels after treatment with aflibercept and ranibizumab...
June 2016: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/27079204/response-to-bevacizumab-after-treatment-with-aflibercept-in-eyes-with-neovascular-amd
#18
Maria Waizel, Annekatrin Rickmann, Björn R Blanke, Katharina Wolf, Sara Kazerounian, Peter Szurman
PURPOSE: To study the visual outcome and change in central macular thickness (CMT) in patients with neovascular age-related macular degeneration (AMD) who were previously treated with aflibercept (VEGF Trap-Eye, Eylea) and were subsequently switched to bevacizumab (Avastin). METHODS: In this observational analysis, 19 eyes initially treated with at least 3 injections of bevacizumab after initial treatment with at least 3 injections of aflibercept are reported. Outcome measures were Snellen visual acuity (best-corrected visual acuity (BCVA) and CMT measured by spectral-domain optical coherence tomography...
August 4, 2016: European Journal of Ophthalmology
https://www.readbyqxmd.com/read/27078613/flattening-of-a-treatment-resistant-retinal-pigment-epithelial-detachment-after-a-single-intravitreal-injection-of-ziv-aflibercept
#19
Rohit Yogi, Michael Stewart, Jay Chhablani
PURPOSE: To report flattening of a treatment-resistant retinal pigment epithelial detachment (PED) due to neovascular age-related macular degeneration after a single intravitreal injection of ziv-aflibercept (Zaltrap). METHODS: A 67-year-old woman with a neovascular age-related macular degeneration-related PED was treated with intravitreal injections of bevacizumab and ranibizumab, and in combination with verteporfin photodynamic therapy, before receiving a single intravitreal injection of ziv-aflibercept (1...
April 13, 2016: Retinal Cases & Brief Reports
https://www.readbyqxmd.com/read/27030277/three-month-outcome-of-ziv-aflibercept-for-exudative-age-related-macular-degeneration
#20
Ahmad M Mansour, Jay Chhablani, Rafic S Antonios, Rohit Yogi, Muhammad H Younis, Rola Dakroub, Hasan Chahine
PURPOSE: In vitro and in vivo studies did not detect toxicity to the retinal pigment epithelium cells using intravitreal ziv-aflibercept. Our purpose is to ascertain the 3-month safety and efficacy in wet age-related macular degeneration (AMD) treated with intravitreal ziv-aflibercept. METHODS: Prospectively, consecutive patients with wet AMD underwent ziv-aflibercept intravitreal injection (1.25 mg/0.05 mL) from March 2015 to November 2015. Monitoring of best-corrected visual acuity, intraocular inflammation, cataract progression and by spectral domain optical coherence tomography were carried out at baseline day 1, 1 week, 1 month, 2 months and 3 months after injections...
March 30, 2016: British Journal of Ophthalmology
keyword
keyword
1764
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"